The addition of EGFR-mAbs to gemcitabine-based first-line CHT does not significantly improve overall and progression-free survival, nor the objective response rate in patients with advanced BTC and increases the risk of hematological and cutaneous adverse drug events.
No takes yet. Share an insight, caveat, or question.
Rizzo et al. (2020) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: